RVLPQ OTC
RVL Pharmaceuticals plc
1W: +900.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$50M
+184.1% ▲
5Y CAGR: -27.4%
Gross Profit
$40M
+190.0% ▲
5Y CAGR: -19.5%
Operating Income
-$59M
+25.1% ▲
Net Income
-$52M
+20.4% ▲
EPS (Diluted)
$-0.58
+39.6% ▲
EBITDA
-$48M
+32.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $264M | $240M | $28M | $18M | $50M |
| YoY Growth | +7.3% | -9.0% | -88.4% | -37.0% | +184.1% |
| Cost of Revenue | $142M | $112M | $3M | $4M | $9M |
| Gross Profit | $122M | $128M | $24M | $14M | $40M |
| Gross Margin | 46.2% | 53.5% | 88.1% | 79.3% | 81.0% |
| R&D Expenses | $44M | $32M | $13M | $7M | $4M |
| SG&A Expenses | $72M | $93M | $73M | $87M | $82M |
| Operating Expenses | $116M | $125M | $86M | $97M | $99M |
| Operating Income | $6M | -$281M | -$62M | -$79M | -$59M |
| Operating Margin | 2.2% | -116.9% | -222.4% | -449.7% | -118.6% |
| Interest Expense | $21M | $18M | $4M | $4M | $3M |
| Income Before Tax | -$119M | -$298M | -$95M | -$83M | -$52M |
| Tax Expense | -$9M | -$27M | -$6M | $315K | -$20K |
| Net Income | -$110M | -$271M | -$80M | -$65M | -$52M |
| Net Margin | -41.6% | -112.9% | -286.7% | -371.0% | -104.0% |
| EPS (Diluted) | $-2.42 | $-5.17 | $-1.31 | $-0.96 | $-0.58 |
| EBITDA | -$16M | -$223M | -$70M | -$71M | -$48M |
| Shares Outstanding | 45M | 52M | 61M | 67M | 90M |